BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20154618)

  • 1. Recent updates in renal cell carcinoma.
    Rathmell WK; Godley PA
    Curr Opin Oncol; 2010 May; 22(3):250-6. PubMed ID: 20154618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on targeted therapies for clear cell renal cell carcinoma.
    Singer EA; Gupta GN; Srinivasan R
    Curr Opin Oncol; 2011 May; 23(3):283-9. PubMed ID: 21330923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in renal cell carcinoma.
    D'Avella C; Abbosh P; Pal SK; Geynisman DM
    Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inherited forms of renal cell carcinoma.
    Kiuru M; Kujala M; Aittomäki K
    Scand J Surg; 2004; 93(2):103-11. PubMed ID: 15285561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.
    Rathmell WK; Chen S
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):63-73. PubMed ID: 18095884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal cell carcinoma: basic biology and clinical behavior.
    Franklin JR; Figlin R; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):208-15. PubMed ID: 8946619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
    Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
    BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and Management of Hereditary Renal Cell Cancer.
    Menko FH; Maher ER
    Recent Results Cancer Res; 2016; 205():85-104. PubMed ID: 27075350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma: current status and emerging therapies.
    Nelson EC; Evans CP; Lara PN
    Cancer Treat Rev; 2007 May; 33(3):299-313. PubMed ID: 17329029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular genetic mechanism of the kidney cancer].
    Nakaigawa N; Yao M; Kishida T; Kubota Y
    Nihon Rinsho; 2001 Jan; 59(1):104-9. PubMed ID: 11197838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy in renal cell carcinoma.
    Gul A; Rini BI
    Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.
    Kim BJ; Kim JH; Kim HS; Zang DY
    Oncotarget; 2017 Feb; 8(8):13979-13985. PubMed ID: 28103578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.